newsfilter
← Latest News
PR Newswire·

Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

ATNM
  • Actinium Pharmaceuticals announced that the RADIANZ clinical trial is enrolling patients to guide the pan-cancer development of ATNM-400 for advanced HER3-expressing solid tumors beyond prostate cancer.
  • RADIANZ is an imaging study utilizing ⁸⁹Zr-Barecetamab-DFO PET scans to evaluate biodistribution, tumor uptake, pharmacokinetics, & dosimetry across tumor types including NSCLC, breast, colorectal, pancreatic, & ovarian cancers.
  • The study builds on initial first-in-human Phase 1 data for ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC) presented at EANM 2026 & ESMO 2026, where the first three patients showed no dose-limiting toxicities & tumor uptake retained through Day 7.
  • Preclinical translational data supports ATNM-400's potential as a single agent or in combination with approved drugs across non-small cell lung, breast, colorectal, & ovarian cancer models.
  • ATNM-400 is an investigational first-in-class Actinium-225 antibody radioconjugate targeting HER3, offering a differentiated approach from PSMA-targeted therapies for patients with PSMA-low/negative disease or resistance.
  • The Company plans to present additional breast cancer data for ATNM-400 at the San Antonio Breast Cancer Symposium (SABCS) from December 8-11, 2026.
  • HER3 targeting is a key differentiator for ATNM-400, as the antigen is implicated in tumor survival & treatment resistance across multiple solid tumor types.
  • Actinium's pipeline includes ATNM-400 for solid tumors, Actimab-A for AML/MDS in collaboration with the NCI, & targeted conditioning agents like Iomab-B, supported by approximately 250 patents.
Company
Actinium Pharmaceuticals, Inc.
Keywords
Actinium Pharmaceuticals, Inc.